Reuters Excerpt: "LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer (PFE.N), opens new tab, $230 billion Novartis (NOVN.S), opens new tab and $216 billion Roche (ROG.S), opens new tab are converging with newer players like $121 billion Vertex Pharmaceuticals (VRTX.O), opens new tab. As drugmakers wrestle with the need to constantly replenish their stocks of remedies via deals, big names may struggle to remain relevant.

https://www.reuters.com/breakingviews/new-pha...024-06-11/